Cardiovascular Systems Sponsoring Orbital Atherectomy Sessions at iCON 2013

  Cardiovascular Systems Sponsoring Orbital Atherectomy Sessions at iCON 2013

Business Wire

ST. PAUL, Minn. & SCOTTSDALE, Ariz. -- February 19, 2013

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), announced today it is
sponsoring a challenging case presentation featuring its peripheral orbital
atherectomy system, and co-hosting an office-based lab presentation and
breakfast session at the International Congress for Endovascular Specialties
(iCON) 2013 conference in Scottsdale, Ariz., Feb. 24-28, 2013.

CSI-Sponsored Challenging Case Presentation: Feb. 25

WHAT: Dr. Robert J. Feezor, University of Florida Vascular Surgery,
Gainesville, Fla., will present “Challenging Case: Percutaneous Orbital
Atherectomy in Lieu of Surgical Reconstruction.” Learn how patients with
complex and calcified peripheral disease can be treated with a new technology,
rather than surgery.

    WHEN:    Monday, Feb. 25, 2:30 – 3:30 p.m.

    WHERE:   Westin Kierland
             6902 East Greenway Parkway
             Scottsdale, AZ 85254

Breakfast Session Co-sponsored by CSI: Feb. 28

WHAT: Dr. Warren Swee, South Florida Vascular Associates, Coconut Creek, Fla.,
and Dr. Raju Gandhi, Mills-Peninsula Health Services, Burlingame, Calif., will
present “Exploring the Future of the Interventional Office Practice” during a
breakfast session hosted by CSI, National Cardiovascular Partners and Ziehm
Imaging. Learn how physicians are treating patients in this rapidly growing

    WHEN:    Thursday, Feb. 28, 7 – 8 a.m.

    WHERE:   Westin Kierland
             6902 East Greenway Parkway
             Scottsdale, AZ 85254

About Peripheral Arterial Disease
PAD is a life-threatening condition where a fatty material called plaque
builds up on the inside walls of the blood vessels that carry blood from the
heart to legs and arms. The plaque buildup causes the arteries to harden and
narrow (atherosclerosis), reducing blood flow to the legs. The risk of PAD
increases if a person has one or several of the following: high blood
pressure, abnormal cholesterol levels, diabetes, or personal history of heart
disease, heart attack or stroke. PAD affects an estimated 8-12 million people
in the United States. The disease prevalence increases with age and 12-20
percent of Americans age 65 and older suffer from PAD symptoms. As the U.S.
population ages, the prevalence range could reach 16 million in those age 65
and older and 19 million overall by 2050.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device
company focused on developing and commercializing innovative solutions for
treating vascular and coronary disease. The company’s Orbital Atherectomy
Systems treat calcified and fibrotic plaque in arterial vessels throughout the
leg in a few minutes of treatment time, and address many of the limitations
associated with existing surgical, catheter and pharmacological treatment
alternatives. The U.S. FDA granted 510(k) clearance for the use of the
Diamondback Orbital Atherectomy System in August 2007. To date, over 100,000
of CSI’s devices have been sold to leading institutions across the United
States. CSI has also commenced its ORBIT II Investigational Device Exemption
clinical trial to evaluate the safety and effectiveness of its orbital
technology in treating coronary arteries. The coronary system is limited by
federal law to investigational use and is currently not commercially available
in the United States.

For more information, visit the company’s website at


Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
Sarah Wozniak, 651-259-1636
Padilla Speer Beardsley Inc.
Matt Sullivan, 612-455-1709
Dave Folkens, 612-455-1741
Press spacebar to pause and continue. Press esc to stop.